Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-EX02 CAR-T in Pancreatic and Bile Duct Cancer
NCT06196658Phase 1Not yet recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of anti-EX02 CAR T cells in pancreatic cancer (PC) and cholangiocarcinoma (CCA). Primary endpoints: Treatment-Related Adverse Events at 4 weeks and Objective Response Rate at 24 weeks. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
anti-EX02 CAR T cells
03
Conditions
pancreatic cancer (PC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06196658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196658.